Evomela Approved as Pre-transplant Conditioning Therapy for Multiple Myeloma Patients in China
Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will…
News
KappaMab, an Antibody, Shows Safety and Hints of Efficacy in Myeloma Patients in Early Trial
KappaMab (MDX-1097), a new monoclonal antibody that binds to the kappa myeloma antigen, has a favorable safety profile in multiple myeloma patients with excess kappa…
Triple Therapies Best, But Revlimid with Dexamethasone Could Work in Some Difficult-to-Treat Myelomas, Study Shows
Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM), combining this therapy with…
‘Moving Mountains for Multiple Myeloma’ Takes Trek Challenge to Iceland
Aiming to both inspire the multiple myeloma community and raise money to accelerate treatments, members of Moving Mountains for Multiple Myeloma (MM4MM) recently traversed…
AJMC Introduces 14-part Video Series on Multiple Myeloma Treatment
A new video series by the American Journal of Managed Care (AJMC) features experts discussing issues related to multiple myeloma treatment. Called “…
clonoSEQ Assay Approved in New York to Measure MRD in Myeloma, Other Blood Cancers
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow, blood, or tissue sample —…
First Patient Dosed in Phase 1 Trial of Antibody for Advanced Multiple Myeloma, Teneobio Announces
A Phase 1 trial evaluating Teneobio’s bispecific antibody TNB-383B as a treatment for multiple myeloma has started dosing patients. This safety and tolerability trial…
Tally of Risk Factors Can Identify Myeloma Patients at Risk of Deep-vein Blood Clots, Study Suggests
A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side…
Donor-derived CAR T-cell Therapy ALLO-715 Enters Clinical Testing for Multiple Myeloma
Allogene Therapeutics is launching the first clinical trial testing ALLO-715, its “off-the-shelf” CAR T-cell therapy, for people with multiple myeloma who failed…
CHMP Favors Empliciti Triple Combo to Treat Advanced Multiple Myeloma Patients in EU
The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that Empliciti (elotuzumab)…
